Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lanifibranor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,643Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inventiva to Present Ph 2 Lanifibranor & Empagliflozin Data at AASLD
    Inventiva to Present Ph 2 Lanifibranor & Empagliflozin Data at AASLD

    15 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/15/2982240/0/en/Inventiva-will-present-data-from-the-final-analysis-of-the-Phase-2-study-evaluating-the-combination-of-lanifibranor-with-empagliflozin-in-patients-with-MASH-and-T2D-at-the-AASLD-Th.html

    GLOBENEWSWIRE
    15 Nov 2024
    Share Share
    Inventiva Receives Positive NATiV3 Phase 3 DMC Recommendation
    Inventiva Receives Positive NATiV3 Phase 3 DMC Recommendation

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2972018/0/en/Inventiva-announces-the-positive-recommendation-of-the-fifth-DMC-of-the-NATiV3-Phase-3-clinical-trial-with-lanifibranor-in-patients-with-MASH.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Inventiva Gets New Patent In Japan For Lanifibranor
    Inventiva Gets New Patent In Japan For Lanifibranor

    25 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/25/2919173/0/en/Inventiva-secures-a-new-patent-in-Japan-expanding-the-IP-protection-of-its-lead-product-candidate-lanifibranor.html

    GLOBENEWSWIRE
    25 Jul 2024
    Share Share
    Inventiva announces a €20.1 million issuance of royalty certificates
    Inventiva announces a €20.1 million issuance of royalty certificates

    18 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/18/2915047/0/en/Inventiva-announces-a-20-1-million-issuance-of-royalty-certificates.html

    GLOBENEWSWIRE
    18 Jul 2024
    Share Share
    Inventiva Updates On NATiV3 Program For Lanifibranor In MASH/NASH And Finances
    Inventiva Updates On NATiV3 Program For Lanifibranor In MASH/NASH And Finances

    05 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/05/2909179/0/en/Inventiva-provides-an-update-on-its-NATiV3-clinical-program-evaluating-lanifibranor-in-patients-with-MASH-NASH-and-its-financial-position.html

    GLOBENEWSWIRE
    05 Jul 2024
    Share Share
    Inventiva Announces Positive Lanifibranor DMC Recommendation In NATiV3
    Inventiva Announces Positive Lanifibranor DMC Recommendation In NATiV3

    16 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/16/2883850/0/en/Inventiva-announces-the-positive-recommendation-of-the-fourth-DMC-of-the-NATiV3-Phase-III-clinical-trial-with-lanifibranor-in-patients-with-MASH-NASH.html

    GLOBENEWSWIRE
    16 May 2024
    Share Share